Collegium Pharmaceutical Receives $22,500,000 New Funding Round

  • Feed Type
  • Date
  • Company Name
    Collegium Pharmaceutical
  • Mailing Address
    400 Highland Corporate Drive Cumberland, RI 02864
  • Company Description
    Collegium Pharmaceutical is dedicated to the development of proprietary, late stage pharmaceutical products that add market value and clinical benefit to existing drugs. We apply customized pharmaceutical formulations and intellectual property (IP) strategies to drugs that are safe and effective, creating a portfolio of improved pharmaceutical products with a shorter time to market.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The round will fund the company for three years. In that time, it expects to file for U.S. approval of a version of oxycodone designed to be harder to tamper with than existing forms of this opioid narcotic.
  • M&A Terms
  • Venture Investor
    Longitude Capital Management
  • Venture Investor
    Skyline Ventures
  • Venture Investor
    Boston Millennia Partners
  • Venture Investor
    Frazier Healthcare Ventures

Trending on Xconomy